Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
Corcept Shares Rise More Than 45% in Six Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
by Zacks Equity Research
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
ALNY Down Despite Positive Data From Heart Disease Drug Study
by Zacks Equity Research
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
by Zacks Equity Research
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
by Zacks Equity Research
The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
by Zacks Equity Research
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
by Zacks Equity Research
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
by Zacks Equity Research
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
by Zacks Equity Research
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
Insmed Stock Surges 168% in the Past Six Months: Here's Why
by Zacks Equity Research
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
by Zacks Equity Research
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay
by Zacks Equity Research
Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay are included in this Analyst Blog.
5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts
by Nalak Das
We have narrowed our search to five small-cap stocks that have strong momentum. These are FULC, HRTG, SWIM, SHIP and BWAY.
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
by Zacks Equity Research
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
by Zacks Equity Research
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
by Zacks Equity Research
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
by Zacks Equity Research
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.